DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Minocycline in Primary Sclerosing Cholangitis (PSC)

Information source: Mayo Clinic
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Primary Sclerosing Cholangitis

Intervention: Minocycline (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Mayo Clinic

Official(s) and/or principal investigator(s):
Keith D. Lindor, M.D., Principal Investigator, Affiliation: Mayo Clinic

Summary

The purpose of the study is to see how safe and effective minocycline is in the treatment of Primary Sclerosing Cholangitis (PSC).

Clinical Details

Official title: Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC)

Study design: Treatment, Single Group Assignment

Primary outcome: To evaluate the safety and estimate the efficacy at the maximally tolerated dose, 100 mg BID, in 30 patients with PSC.

Detailed description: The purpose of the study is to determine the safety profile of minocycline in patients with PSC and to compare the effects of minocycline on the baseline values of the following parameters: symptoms of pruritus and fatigue, liver biochemistries, Mayo Risk Score, the development of clinical progression and complications of liver disease.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Both genders

- Females of childbearing age must have negative pregnancy test within 48 hours of

participation and agreement to practice contraception for the duration of the study.

- Age 18 years old and < than 75 years old.

- History of chronic cholestatic disease of at least 6 months duration.

- Serum alkaline phosphatase level at least 1. 5 times the upper limit of normal.

- Cholangiography demonstrating intrahepatic and/or extrahepatic biliary obstruction,

beading, or narrowing consistent with PSC.

- Liver biopsy consistent with the diagnosis of PSC.

- Patient's informed consent for study participation.

Exclusion Criteria:

- Treatment with tetracyclines, ursodeoxycholic acid, corticosteroids, colchicine,

methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, perfenidone, nicotine, tacrolimus, silymarin, vitamin E or prednisone in the preceding three months.

- Findings highly suggestive of hepatobiliary disease of other etiology complicating

PSC.

- Anticipated need for liver transplantation in one year determined by the Mayo model

with an estimate of <75% one year survival without transplantation.

- Recurrent variceal bleeding, presence of ascites, or encephalopathy.

- Active drug or alcohol use.

- Pregnancy.

- Breast-feeding.

- Serum creatinine over 1. 5 mg/dl.

- Prior history of allergic reactions to antibiotics belonging to the tetracycline

family.

- Any condition that, in the opinion of the investigator, would interfere with the

patient's ability to complete the study safely or successfully.

- Patients with active inflammatory bowel disease (IBD) requiring specific treatment in

the preceding three months, except for maintenance therapy with 5-ASA compounds, or those individuals who have been involved in a trial evaluating any experimental drug for the treatment of IBD in the preceding three months.

- Recurrent ascending cholangitis requiring hospitalization in the past year.

Locations and Contacts

Mayo Clinic, Rochester, Minnesota 55905, United States
Additional Information

Starting date: February 2003
Ending date: May 2007
Last updated: February 27, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009